Results for
""Insulin Glargine""[mesh_terms]

Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial.

Ricardo Gomez Huelgas, Mireia Borrell, Javier Ena, Carlos Trescolí, José Miguel Seguí-Ripoll, Carlos González, Francisco Javier Carrasco-Sánchez, Antonio Perez

BMJ open diabetes research & care 2021;8(1):e001518

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.

Francesco Giorgino, Alka Shaunik, Minzhi Liu, Aramesh Saremi

Diabetes, obesity & metabolism 2020;21(12):2712-2717

Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.

Anoop Misra, Ritu Singh, Akriti Singh, Awadhesh Kumar Singh

Diabetes & metabolic syndrome 2022;16(9):102615

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes.

Ivana Rabbone, Claudio Maffeis

Paediatric drugs 2022;24(5):499-512

Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial.

Hyejung Jung, Jackie Bosch, Giatgen A Spinas, Seamus Sreenan, Patrick Commerford, Hertzel C Gerstein, Melanie J Davies, Tom Yates

Diabetes research and clinical practice 2018;132():137-143

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.

Pablo F Mora, Jason Chao, Aramesh Saremi, Terry A Dex, Michelle Roberts, Guillermo E Umpierrez

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019;25(11):1091-1100

Adoption of Gla-100 in India and its Impact on Insulin Usage Patterns.

Sujeet Jha, Ranjit Unnikrishnan, Sushil Kiran Kunder, Radhika V Kumar, Sridevi Atluri, G D Ramchandani, Biplab Bandopadhyay, Subodh Banzal, K D Modi, Viswanathan Mohan

The Journal of the Association of Physicians of India 2020;68(12[Special]):25-30

Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.

Fu-peng Liu, Jian-jun Dong, Qing Yang, Xian-zhong Xue, Zhong-fa Ren, Yi-zhang Gan, Lin Liao

Journal of diabetes 2016;7(3):322-8

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Agustina Alvarez, Mir-Masoud Pourrahmat, Paul Serafini, Olesya Y Gurova, Khadija A S Hafidh, Roopa Mehta, Philip D Home

Diabetes, obesity & metabolism 2021;23(12):2660-2669

Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.

André J Scheen, Gérald E Piérard, Régis P Radermecker

American journal of clinical dermatology 2007;8(1):21-8

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.

Giorgio Sesti, Lars Bardtrum, Selcuk Dagdelen, Natalie Halladin, Martin Haluzík, Petra Őrsy, Martin Rodríguez, Vanita R Aroda

Diabetes, obesity & metabolism 2021;22(5):873-878

The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.

Thibault Gautier, Guillermo Umpierrez, Eric Renard, Boris Kovatchev

Journal of diabetes science and technology 2021;15(2):371-376

A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.

Yongjia Ji, Feng Wang, Hui Liu, Tianyang Ma, Yerong Yu, Lai San Tham, Laiyi Chua, Helle Linnebjerg, Hongying Li

Clinical pharmacology in drug development 2022;10(12):1452-1459

Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.

Chutintorn Sriphrapradang, Kitti Thammakosol

Diabetes, obesity & metabolism 2023;25(3):815-822